Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Eleanor Malone
Emerging Company Profile: Horizon Discovery’s former CEO Darrin Disley talks to Scrip about the importance of Mogrify’s revolutionary platform for converting cells into any state without the need to create stem cells and force them through evolutionary biology.
Amid ongoing manufacturing issues with its own HRT patches, women’s health spin-out Theramex acquires global rights to Janssen’s Evorel patches, also in shortage.
Novartis’s investigational oral therapy for asthma fell at the first Phase III hurdle but pivotal studies in severe disease will be key to prospects.
UCB and Amgen’s osteoporosis drug Evenity has been given a positive opinion in Europe after initial rejection. But cardiovascular safety concerns and rival products constrain sales potential.
Tender deadline for Roche acquisition of Spark pushed back to 30 October; 21.4% of Spark shares tendered so far. Vertex further diversifies with fourth deal of 2019 – an RNA-targeted collaboration with Ribometrix.
The future looks rosy after a slow start for antibody-drug conjugates. But what are the best tactics to capture a slice of the growing opportunity?